论文部分内容阅读
目的:通过体外实验研究病炎清4号方抗呼吸道合胞病毒(RSV)作用,并进行临床验证。方法:以RSV感染培养的细胞,分别加入病炎清4号方、病毒唑,测算两者的治疗指数并比较;通过临床观察病炎清4号方对急性RSV感染患者的疗效(以病毒唑治疗作为对照)。结果:病炎清4号方的TI值大于病毒唑(P<0.05);治疗组疗效显著优于对照组(P<0.05)。结论:病炎清4号方为有效的抗RSV复方。
Objective: To study the anti-respiratory syncytial virus (RSV) effect of Yiyanqing No. 4 prescription in vitro and verify it clinically. METHODS: The cultured cells were infected with RSV, and were added to SJ4 and Ribavirin, respectively, and their therapeutic indices were calculated and compared. Clinical efficacy of SJ4F in patients with acute RSV infection was observed by clinical observation. Treatment as a control). RESULTS: The TI value of SFI 4 was higher than that of ribavirin (P<0.05). The efficacy of the treatment group was significantly better than that of the control group (P<0.05). Conclusion: Sick Yanqing No. 4 is an effective anti-RSV compound.